The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that could see proceeds of around $210m. The cancer treatment-focused biotech ...
Jersey Mike’s reveals how modern IPOs transfer risk to investors while insiders exit. Why IPOs are liquidity events, not ...
Hosted on MSN
2026’s IPO lineup is getting dangerous
Something big is lining up for 2026, and it’s not just another IPO cycle. Wall Street is staring at one of the most crowded public-market queues in years, with 190+ companies racing toward the exit at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results